IDIBELL-Bellvitge Biomedical Research Institute

The Bellvitge Biomedical Research Institute (IDIBELL) was created in 2004. It is the foundation that manages the research activities of Bellvitge University Hospital, the Catalan Oncology Institute, the Bellvitge campus of the University of Barcelona, and the public health companies Institut de Diagnòstic per la Imatge (Image Diagnosis Institute) and Banc de Sang i Teixits (Blood and Tissue Bank). The Institute is the core of Biopol, the health research park of Hospitalet de Llobregat, in the South of Barcelona. The president of the IDIBELL’s managing board is the Catalan Minister of Health, Marina Geli. IDIBELL has more than 500 researchers and manages a budget of almost 22 million euros. The Foundation’s main scientific partners are the University of Barcelona, the Catalan Oncology Institute and the Catalan Health Institute (the managing company of the Bellvitge University Hospital). Since March 2009, it is one of the five research centers accredited by the Spanish Ministry of Health.

Some content from Wikipedia, licensed under CC BY-SA

Dog's epigenome gives clues to human cancer

The bond between humans and dogs is strong and ancient. From being the protector of the first herds in a faithful pet, dogs and people share many aspects of life. The relationship between the two species ...

Oct 02, 2014
popularity 4 / 5 (6) | comments 0

XenOPAT, mouse models for personalized cancer treatment

On September 8th, the company XenOPAT SL, a spin-off of the Institute of Biomedical Research (IDIBELL) and the Catalan Institute of Oncology (ICO) was established with the aim of bringing the company the latest scientific ...

Sep 23, 2014
popularity not rated yet | comments 0

Five genes to predict colorectal cancer relapses

Researchers at the Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (ICO-IDIBELL), led by David Garcia-Molleví have identified 5 genes differentially expressed in normal accompanying ...

Sep 17, 2014
popularity 3.5 / 5 (2) | comments 0

New therapeutic combination to slow resistant sarcomas

Researchers at sarcomas research group at the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO) have been tested in 19 patients a new therapeutic combination to ...

Jul 10, 2014
popularity not rated yet | comments 0